We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CytoDyn Inc (QB) | USOTC:CYDY | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.00436 | -3.12% | 0.1356 | 0.132 | 0.14 | 0.14 | 0.1285 | 0.1399 | 1,760,513 | 21:00:07 |
☒ |
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1933
|
Delaware
|
83-1887078
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer or
Identification No.)
|
|
1111 Main Street, Suite 660
Vancouver, Washington
|
98660
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange
on Which Registered
|
None.
|
|
None.
|
|
None.
|
Large Accelerated Filer | ☐ | Accelerated Filer | ☒ | |||
Non-accelerated
Filer
|
☐ | Smaller Reporting Company | ☒ | |||
Emerging Growth Company | ☐ |
|
|
PAGE
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
26
|
|
|
|
|
36
|
|
|
|
|
36
|
|
|
|
|
36
|
|
|
|
|
36
|
|
|
|
|
37
|
|
|
|
|
37
|
|
|
|
|
38
|
|
|
|
|
38
|
|
|
|
|
38
|
|
|
|
|
39
|
|
August 31, 2020
(unaudited) |
May 31, 2020
(audited) |
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash
|
$ | 18,200 | $ | 14,282 | ||||
Restricted cash
|
13 | 10 | ||||||
Inventories
|
58,474 | 19,147 | ||||||
Prepaid expenses
|
828 | 498 | ||||||
Prepaid service fees
|
2,361 | 2,890 | ||||||
|
|
|
|
|||||
Total current assets
|
79,876 | 36,827 | ||||||
Operating lease
s
right-of-use
|
420 | 176 | ||||||
Property and equipment, net
|
107 | 55 | ||||||
Intangibles, net
|
12,959 | 13,456 | ||||||
|
|
|
|
|||||
Total assets
|
$ | 93,362 | $ | 50,514 | ||||
|
|
|
|
|||||
Liabilities and Stockholders’ (Deficit) Equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$ | 21,351 | $ | 29,479 | ||||
Accrued liabilities and compensation
|
34,419 | 6,866 | ||||||
Accrued license fees
|
148 | 13 | ||||||
Accrued interest on convertible notes
|
858 | 292 | ||||||
Accrued dividends on convertible preferred stock
|
1,401 | 981 | ||||||
Current portion of operating leases payable
|
110 | 115 | ||||||
Current portion of long-term convertible notes payable
|
18,124 | 6,745 | ||||||
Warrant
exercise
proceeds held in trust
|
13 | 10 | ||||||
|
|
|
|
|||||
Total current liabilities
|
76,424 | 44,501 | ||||||
|
|
|
|
|||||
Long-term liabilities:
|
||||||||
Convertible notes payable, net
|
13,856 | 8,431 | ||||||
Operating lease
s
liability
|
314 | 63 | ||||||
|
|
|
|
|||||
Total long-term liabilities
|
14,170 | 8,494 | ||||||
|
|
|
|
|||||
Total liabilities
|
90,594 | 52,995 | ||||||
|
|
|
|
|||||
Commitments and Contingencies (
Note
10)
|
|
|
||||||
Stockholders’ (Deficit)
Equity
|
||||||||
Preferred
s
tock, $0.001 par value; 5,000 shares authorized
|
||||||||
Series D convertible preferred stock, $0.001 par value; 12 authorized; 9 issued and outstanding at
August 31, |
— | — | ||||||
Series C convertible preferred stock, $0.001 par value; 8 authorized; 8 issued and outstanding at August 31,
and May 31, 2020, respectively |
— | — | ||||||
Series B convertible preferred stock, $0.001 par value; 400 shares authorized, 87 and 92 shares issued and outstanding at August 31, 2020 and May 31, 2020, respectively
|
— | — | ||||||
Common stock, $0.001 par value; 800,000 shares authorized, 570,325 and 519,261 issued and 569,883 and
518,976 outstanding at August 31, 2020 and May 31, 2020, respectively |
570 | 519 | ||||||
Additional paid-in capital
|
388,404 | 351,711 | ||||||
Accumulated (deficit)
|
(386,206 | ) | (354,711 | ) | ||||
Less: treasury stock, $
0.001
par value (442 and 286 shares at August 31, 2020 and May 31, 2020, respectively)
|
— | — | ||||||
|
|
|
|
|||||
Total stockholders’ (deficit) equity
|
2,768 | (2,481 | ) | |||||
|
|
|
|
|||||
Total liabilities and stockholders’ (deficit) equity
|
$ | 93,362 | $ | 50,514 | ||||
|
|
|
|
Three Months Ended | ||||||||
August 31, 2020 | August 31, 2019 | |||||||
Operating expenses:
|
||||||||
General and administrative
|
$ | 9,875 | $ | 3,046 | ||||
Research and development
|
15,188 | 9,055 | ||||||
Amortization and depreciation
|
505 | 531 | ||||||
|
|
|
|
|||||
Total operating expenses
|
25,568 | 12,632 | ||||||
|
|
|
|
|||||
Operating loss
|
(25,568 | ) | (12,632 | ) | ||||
Change in fair value of derivative liabilities
|
— | 625 | ||||||
Interest expense:
|
||||||||
Finance charges
|
(10 | ) | (8 | ) | ||||
Amortization of discount on convertible notes
|
(1,339 | ) | (1,030 | ) | ||||
Amortization of debt issuance costs
|
(4 | ) | (284 | ) | ||||
Inducement interest - warrant exercises and debt
conversion
|
(3,345 | ) | (2,431 | ) | ||||
Interest on convertible note
s
payable
|
(566 | ) | (404 | ) | ||||
|
|
|
|
|||||
Total interest expense
|
(5,264 | ) | (4,157 | ) | ||||
|
|
|
|
|||||
Loss before income taxes
|
(30,832 | ) | (16,164 | ) | ||||
Income tax benefit
|
— | — | ||||||
|
|
|
|
|||||
Net loss
|
$ | (30,832 | ) | $ | (16,164 | ) | ||
|
|
|
|
|||||
Basic and diluted loss per share
|
$ | (0.06 | ) | $ | (0.04 | ) | ||
|
|
|
|
|||||
Basic and diluted weighted average common shares outstanding
|
555,531 | 364,639 | ||||||
|
|
|
|
Preferred Stock | Common Stock | Treasury Stock | ||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||
Balance May 31, 2020
|
109 | $ | — | 519,261 | $ | 519 | 286 | $ | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
First Quarter Fiscal Year Ended May 31, 2021
|
||||||||||||||||||||||||
Issuance of stock for convertible note conversions
|
— | — | 2,119 | 2 | — | — | ||||||||||||||||||
Issuance of legal settlement shares
|
— | — | 4,000 | 4 | — | — | ||||||||||||||||||
Exercise of stock options
|
— | — | 100 | — | — | — | ||||||||||||||||||
Stock issued for incentive compensation and tendered for income tax
|
— | — | 323 | — | 156 | — | ||||||||||||||||||
Conversion of Series B
convertible preferred share
s to common stock
|
(5 | ) | — | 50 | — | — | — | |||||||||||||||||
Private warrant exchange
|
— | — | 16,544 | 17 | — | — | ||||||||||||||||||
Exercise of warrants
|
— | — | 19,134 | 19 | — | — | ||||||||||||||||||
Cashless exercise of warrants
|
— | — | 8,794 | 9 | — | — | ||||||||||||||||||
Inducement interest expense related to private warrant exchange
|
— | — | — | — | — | — | ||||||||||||||||||
Offering costs related to private warrant exchange
|
— | — | — | — | — | — | ||||||||||||||||||
Dividend declared and paid on Series B
p
referred shares ($0.25/share)
|
— | — | — | — | — | — | ||||||||||||||||||
Dividends on Series C
p
referred shares
|
— | — | — | — | — | — | ||||||||||||||||||
Dividends on Series D
p
referred shares
|
— | — | — | — | — | — | ||||||||||||||||||
Stock-based compensation
|
— | — | — | — | — | — | ||||||||||||||||||
Net
l
oss August 31, 2020
|
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance August 31, 2020
|
104 | $ |
—
|
570,325 | $ | 570 | 442 | $ | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock | Common Stock | Treasury Stock | ||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | |||||||||||||||||||
Balance May 31, 2019
|
95 | $ | — | 329,554 | $ | 330 | 159 | $ | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
First Quarter Fiscal Year Ended May 31, 2020
|
||||||||||||||||||||||||
Issuance of stock for note payable redemption
|
— | — | 3,014 | 3 | — | — | ||||||||||||||||||
Proceeds from registered direct offering ($0.50/share)
|
— | — | 5,640 | 6 | — | — | ||||||||||||||||||
Offering costs related to registered direct offering
|
— | — | — | — | — | — | ||||||||||||||||||
Proceeds from public warrant tender offers
|
— | — | 45,376 | 45 | — | — | ||||||||||||||||||
Offering costs related to public warrant tender offers
|
— | — | ||||||||||||||||||||||
Inducement interest expense — public warrant tender offers
|
— | — | — | — | — | — | ||||||||||||||||||
Proceeds from Series C
p
referred offering
|
2 | — | ||||||||||||||||||||||
Offering costs related to Series C
p
refe
r
red offering
|
— | — | — | — | — | — | ||||||||||||||||||
Dividends on Series C
p
referred shares
|
— | — | — | — | — | — | ||||||||||||||||||
Legal fees in connection with equity offerings
|
— | — | — | — | — | — | ||||||||||||||||||
Stock-based compensation
|
— | — | — | — | — | — | ||||||||||||||||||
Net
l
oss August 31, 2019
|
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Balance August 31, 2019
|
97 | $ | — | 383,584 | $ | 384 | 159 | $ | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Additional
Paid-In Capital
|
Accumulated
Deficit |
Total | ||||||||||
Balance May 31, 2020
|
$ | 351,711 | $ | (354,711 | ) | $ | (2,481 | ) | ||||
|
|
|
|
|
|
|||||||
First Quarter Fiscal Year Ended May 31, 2021
|
||||||||||||
Issuance of stock for convertible note conversions
|
9,535 | — | 9,537 | |||||||||
Issuance of legal settlement shares
|
(4 | ) | — | — | ||||||||
Exercise of stock options
|
39 | — | 39 | |||||||||
Stock issued for incentive compensation and tendered for income tax
|
828 | — | 828 | |||||||||
Conversion of Series B
c
onvertible
p
referred
s
to
hares
c
ommon
s
tock
|
— | — | — | |||||||||
Private warrant exchange
|
7,787 | — | 7,804 | |||||||||
Exercise of warrants
|
13,450 | — | 13,469 | |||||||||
Cashless exercise of warrants
|
(9 | ) | — | — | ||||||||
Inducement interest expense related to private warrant exchange
|
3,345 | — | 3,345 | |||||||||
Offering costs related to private warrant exchange
|
(364 | ) | — | (364 | ) | |||||||
Dividend declared and paid on Series B
p
referred shares ($0.25
/
share)
|
— | (243 | ) | (243 | ) | |||||||
Dividends on Series C
p
referred shares
|
— | (207 | ) | (207 | ) | |||||||
Dividends on Series D
p
referred shares
|
— | (213 | ) | (213 | ) | |||||||
Stock-based compensation
|
2,086 | — | 2,086 | |||||||||
Net
l
oss August 31, 2020
|
— | (30,832 | ) | (30,832 | ) | |||||||
|
|
|
|
|
|
|||||||
Balance August 31, 2020
|
$ | 388,404 | $ | (386,206 | ) | $ | 2,768 | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
Paid-In
Capital
|
Accumulated
Deficit |
Total | ||||||||||
Balance May 31, 2019
|
$ | 220,120 | $ | (229,364 | ) | $ | (8,914 | ) | ||||
|
|
|
|
|
|
|||||||
First Quarter Fiscal Year Ended May 31, 2020
|
||||||||||||
Issuance of stock for note payable redemption
|
1,002 | — | 1,005 | |||||||||
Proceeds from registered direct offering ($0.50/share)
|
2,250 | — | 2,256 | |||||||||
Offering costs related to registered direct offering
|
(260 | ) | — | (260 | ) | |||||||
Proceeds from public warrant tender offers
|
11,855 | — | 11,900 | |||||||||
Offering costs related to public warrant tender offers
|
(1,059 | ) | — | (1,059 | ) | |||||||
Inducement interest expense—public warrant tender offers
|
2,431 | — | 2,431 | |||||||||
Proceeds from
s
eries C
p
referred offering
|
1,754 | — | 1,754 | |||||||||
Offering costs related to Series C
p
ef
r
er
red offering
|
(198 | ) | — | (198 | ) | |||||||
Dividends on
s
eries C
p
referred shares
|
— | (110 | ) | (110 | ) | |||||||
Legal fees in connection with equity offerings
|
(16 | ) | — | (16 | ) | |||||||
Stock-based compensation
|
581 | — | 581 | |||||||||
Net
l
oss August 31, 2019
|
— | (16,164 | ) | (16,164 | ) | |||||||
|
|
|
|
|
|
|||||||
Balance August 31, 2019
|
$ | 238,460 | $ | (245,638 | ) | $ | (6,794 | ) | ||||
|
|
|
|
|
|
Three Months Ended | ||||||||
August 31, 2020 | August 31, 2019 | |||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$ | (30,832 | ) | $ | (16,164 | ) | ||
Adjustments to reconcile net loss to net cash used
i
operating activities:
n
|
||||||||
Amortization and depreciation
|
505 | 531 | ||||||
Amortization of debt issuance costs
|
4 | 284 | ||||||
Amortization of discount on convertible notes
|
1,339 | 1,030 | ||||||
Inducement interest - warrant exercises and debt conversion
|
3,345 | 2,431 | ||||||
Interest expense associated with accretion of convertible notes payable
|
— | 266 | ||||||
Change in fair value of derivative liabilities
|
— | (625 | ) | |||||
Stock-based compensation
|
3,692 | 581 | ||||||
Changes in current assets and liabilities:
|
||||||||
(Increase) in inventories
|
(39,327 | ) | — | |||||
Decrease in prepaid expenses
|
199 | 499 | ||||||
Increase (decrease) in accounts payable and accrued expenses
|
20,127 | (4,023 | ) | |||||
|
|
|
|
|||||
Net cash used in operating activities
|
(40,948 | ) | (15,190 | ) | ||||
|
|
|
|
|||||
Cash flows from investing activities:
|
||||||||
Furniture and equipment purchases
|
(59 | ) | (5 | ) | ||||
|
|
|
|
|||||
Net cash used in investing activities
|
(59 | ) | (5 | ) | ||||
|
|
|
|
|||||
Cash flows from financing activities:
|
||||||||
Proceeds from private warrant exchange, net of offering costs
|
7,441 | 2,256 | ||||||
Proceeds from exercise of warrants
|
13,469 | 1,754 | ||||||
Proceeds from warrant tender offers
|
— | 11,900 | ||||||
Release of funds held in trust for warrant tender offer
|
— | (854 | ) | |||||
Proceeds from exercise of stock options
|
39 | — | ||||||
Payment of payroll witholdings related to tender of common stock for income tax withholding
|
(778 | ) | — | |||||
Proceeds from convertible notes payable, net
of
discount and issuance costs
|
25,000 | — | ||||||
Payment of offering costs
|
— | (1,532 | ) | |||||
Dividend declared and paid on Series
B
p
referred shares
|
(243 | ) | — | |||||
|
|
|
|
|||||
Net cash provided by financing activities
|
44,928 | 13,524 | ||||||
|
|
|
|
|||||
Net change in cash
|
3,921 | (1,671 | ) | |||||
Cash, beginning of period
|
14,292 | 3,467 | ||||||
|
|
|
|
|||||
Cash, end of period
|
$ | 18,213 | $ | 1,796 | ||||
|
|
|
|
|||||
Supplemental disclosure of cash flow information:
|
||||||||
|
$ | 11 | $ | 10 | ||||
|
|
|
|
|||||
Non-cash
investing and financing transactions:
|
||||||||
Issuance of stock for note payable redemption and conversions
|
$ | 9,537 | $ | 1,005 | ||||
|
|
|
|
|||||
Accrued dividends on Series C
c
onvertible
p
referred stock
|
$ | 207 | $ | 110 | ||||
|
|
|
|
|||||
Accrued dividends on Series D
c
onvertible
p
referred stock
|
$ | 213 | $ | — | ||||
|
|
|
|
Investor warrants issued with registered direct equity offering
|
$ | 4,360 | ||
Placement agent warrants issued with registered direct equity offering
|
819 | |||
Fair value adjustments
|
(3,855 | ) | ||
|
|
|||
Balance at May 31, 2018
|
1,324 | |||
Inception date value of redemption provisions
|
2,750 | |||
Fair value adjustments—convertible notes
|
(745 | ) | ||
Fair value adjustments—warrants
|
(922 | ) | ||
|
|
|||
Balance at May 31, 2019
|
2,407 | |||
Fair value adjustments—convertible notes
|
(2,005 | ) | ||
Fair value adjustments—warrants
|
11,547 | |||
Exercise of derivative warrants
|
(11,949 | ) | ||
|
|
|||
Balance at May 31, 2020
|
$ | — | ||
|
|
August 31, 2020
|
May 31, 2020
|
|||||||
Raw materials
|
$ | 20,263 | $ | 19,147 | ||||
Work
-
in
-
pro
gress
|
38,211 | — | ||||||
Total
|
$ | 58,474 | $ | 19,147 | ||||
|
|
|
|
January 30, 2019
|
||||
Fair value of redemption provision
|
$ | 1,465 | ||
Relative fair value of equity classified warrants
|
858 | |||
Beneficial conversion feature
|
2,677 | |||
|
|
|||
Net proceeds of January 2019 Note
|
$ | 5,000 | ||
|
|
Shares
Indexed
|
Derivative
Liability
|
|||||||
Inception to date September 15, 2016
|
7,733 | $ | 5,179 | |||||
Change in fair value of derivative liability
|
— | (4,777 | ) | |||||
|
|
|
|
|||||
Balance May 31, 2019
|
7,733 | 402 | ||||||
Change in fair value of derivative liability
|
— | 11,547 | ||||||
Fair value of warrants exercised
|
7,733 | (11,949 | ) | |||||
|
|
|
|
|||||
Balance May 31, 2020
|
— | — | ||||||
Change in fair value of derivative liability
|
— | — | ||||||
Balance August 31, 2020
|
— | $ | — | |||||
|
|
|
|
September 15,
2016 |
May 31,
2019 |
August 31,
2019 |
||||||||||
Fair value of underlying stock
|
$ | 0.78 | $ | 0.39 | $ | 0.40 | ||||||
Risk free rate
|
1.20 | % | 1.94 | % | 1.50 | % | ||||||
Expected term (in years)
|
5 | 2.29 | 2.04 | |||||||||
Stock price volatility
|
106 | % | 61 | % | 60 | % | ||||||
Expected dividend yield
|
— | — | — | |||||||||
Probability of
f
undamental
t
ransaction
|
50 | % | 50 | % | 50 | % | ||||||
Probability of holder requesting cash payment
|
50 | % | 50 | % | 50 | % |
August 31, 2019
|
||||||||||||||||
|
|
November 15,
2018 |
|
|
January 30,
2019 |
June
Note |
January
Note |
|
||||||||
Fair value of underlying stock
|
$ | 0.57 | $ | 0.49 | $ | 0.40 | $ | 0.40 | ||||||||
Risk free rate
|
2.78 | % | 2.52 | % | 1.76 | % | 1.76 | % | ||||||||
Expected term (in years)
|
1.61 | 2 | 0.82 | 1.42 | ||||||||||||
Stock price volatility
|
58.8 | % | 61 | % | 63.8 | % | 61.6 | % | ||||||||
Expected dividend yield
|
— | — | — | — | ||||||||||||
Discount factor
|
85 | % | 85 | % | 85 | % | 85 | % |
Net Proceeds | Derivative Liability | |||||||||||
Inception date | August 31, 2019 | |||||||||||
Inception date June 2018 Note, November 15, 2018
|
$ | 5,000 | $ | 1,285 | $ | 373 | ||||||
Inception date January 2019 Note, January 30, 2019
|
5,000 | 1,465 | 1,070 | |||||||||
|
|
|||||||||||
$ | 1,443 | |||||||||||
|
|
Number of
Shares |
Weighted
Average Exercise Price |
Weighted
Average Remaining Contractual Life in |
Aggregate Intrinsic
Value |
|||||||||||||
Options and warrants outstanding - May 31, 2020
|
131,361 | $ | 0.65 | 5.79 | $ | 302,961 | ||||||||||
Granted
|
1,495 | $ | 4.10 | — | — | |||||||||||
Exercised
|
(45,301 | ) | $ | 0.60 | — | — | ||||||||||
Forfeited/expired/cancelled
|
(333 | ) | $ | 1.23 | — | — | ||||||||||
|
|
|||||||||||||||
Options and warrants outstanding - August 31, 2020
|
87,222 | $ | 0.70 | 4.13 | $ | 232,949 | ||||||||||
|
|
|||||||||||||||
Outstanding exercisable - August 31, 2020
|
84,375 | $ | 0.67 | 3.99 | $ | 227,520 | ||||||||||
|
|
August 31, 2020 | May 31, 2020 | |||||||
Leronlimab (PRO 140) patent
|
$ | 3,500 | $ | 3,500 | ||||
ProstaGene, LLC intangible asset acquisition
|
15,126 | 15,126 | ||||||
Website development costs
|
20 | 20 | ||||||
Accumulated amortization
|
(5,687 | ) | (5,190 | ) | ||||
|
|
|
|
|||||
Total amortizable intangible assets, net
|
12,959 | 13,456 | ||||||
Patents currently not amortized
|
— | — | ||||||
|
|
|
|
|||||
Carrying value of intangibles, net
|
$ | 12,959 | $ | 13,456 | ||||
|
|
|
|
• |
intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition, and
|
• |
preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
|
101.LAB ** | XBRL Taxonomy Extension Label Linkbase Document. | |
101.PRE ** | XBRL Taxonomy Extension Presentation Linkbase Document. | |
104** | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* |
Management contract or compensatory plan or arrangement.
|
** |
Filed herewith.
|
CYTODYN INC. | ||||||
(Registrant) | ||||||
Dated: October 9, 2020 |
/s/ Nader Z. Pourhassan
|
|||||
Nader Z. Pourhassan | ||||||
President and Chief Executive Officer | ||||||
(Principal Executive Officer) | ||||||
Dated: October 9, 2020 |
/s/ Michael D. Mulholland
|
|||||
Michael D. Mulholland | ||||||
Chief Financial Officer and Treasurer | ||||||
(Principal Financial and Accounting Officer) |
1 Year CytoDyn (QB) Chart |
1 Month CytoDyn (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions